ANAPTYSBIO, INC(ANAB)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-03-31.

ANAPTYSBIO, INC (ANAB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ANAB at 48.4/100 on a 32-signal composite quality model, placing it at rank #1,725 of 2,962 stocks — the bottom half of the AI-ranked universe. ANAB scores in the top quartile across revenue growth (99.3), institutional flow (85.7). Areas of concern include balance sheet strength (19.8) and profitability (25.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ANAPTYSBIO, INC reports quarterly revenue of $25.6M, net income of $-52.9M, free cash flow of $-25.9M. Top institutional holders of ANAB by reported 13-F value include EcoR1 Capital, BlackRock, TANG CAPITAL MANAGEMENT, based on the most recent SEC filings. ANAB trades on the Nasdaq exchange and files with the SEC under CIK 1370053. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ANAPTYSBIO, INC directly from SEC EDGAR.